Nexalin Technology (NXL) Operating Leases (2021 - 2023)

Nexalin Technology's (NXL) quarterly Operating Leases came in at $43026.0 in Q1 2023, up 864.06% quarter-over-quarter from $4463.0 in Q4 2022.

Nexalin Technology (NXL) Operating Leases (2021 - 2023) Analysis & Trends

Nexalin Technology's Operating Leases history runs 3 years deep, the most recent figure standing at $43026.0 for Q1 2023.

  • On a quarterly basis, Operating Leases changed N/A year-over-year to $43026.0 in Q1 2023; TTM through Mar 2023 was $43026.0, a N/A change from a year earlier, with the FY2022 full-year figure at $4463.0, down 95.04% from the prior year.
  • Operating Leases rose to $43026.0 in Q1 2023 per NXL's latest filing, from $4463.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $89934.0 in Q4 2021 and bottomed at $4463.0 in Q4 2022.
  • The 3-year median for Operating Leases is $30330.0 (2022), against an average of $38764.2.
  • Biggest YoY gain for Operating Leases was 95.04% in 2022; the steepest drop was 95.04% in 2022.
  • Year by year, Operating Leases stood at $89934.0 in 2021, then tumbled by 95.04% to $4463.0 in 2022, then jumped by 864.06% to $43026.0 in 2023.
  • Per Business Quant, the three latest NXL Operating Leases figures stand at $43026.0 (Q1 2023), $4463.0 (Q4 2022), and $17634.0 (Q3 2022).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn
9 Smith & Nephew 25.80 Bn 25.22 Bn -
10 Nexalin Technology 9.32 Mn 6.61 Mn 13,133.00

Historic Data

Download Data
DateValue
Mar 31, 2023 43,026.00
Dec 31, 2022 4,463.00
Sep 30, 2022 17,634.00
Dec 31, 2021 89,934.00